All In Biotech

Drug Trial Radar · NCT05434663

Safety Study of Repeat Doses of SUSTOL in Adults

A Phase 4, Open-Label Safety Study of Repeat Doses of SUSTOL in Adult Subjects Receiving Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 13, 2022

Primary completion

Sep 18, 2023

Study completion Sep 18, 2023

Sponsor

Lead sponsor
Heron TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a repeat-dose, single-arm, open-label study that evaluated the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy \[MEC\] or Anthracycline and Cyclophosphamide \[AC\] combination regimen).

Conditions

  • Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

  • SUSTOLDrug

    SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles. Supplied in commercially available SUSTOL kits.

  • SUSTOL kit components for administrationDevice

    Each SUSTOL kit includes 1 sterile glass syringe containing 10 mg granisetron/0.4 mL, 1 sterile 18 Ga 5/8" special thin-walled administration needle, 2 sodium acetate syringe warming pouches, and 1 Point Lok needle protection device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADLTime frame: Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • Gabrail Cancer Center Research

    Canton, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.